Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Advanced Medicine, Bioprocessing - Upstream & Downstream, Analytical Science

Efficient production process for adeno-associated viral vectors

sponsored by Cytiva

Available On-Demand

November 12, 2020 at 17:00 UK

Speaker: Dr. Mats Lundgren

The use of adenovirus-associated virus (AAV) vectors in gene therapy is growing. To manufacture safe and efficacious clinical-grade virus, scalable and cost-effective production processes are needed. Here we present an efficient process for AAV production in suspension cell culture to purified bulk product. Each process step was evaluated and optimized. Cell culture conditions and triple-plasmid transfection were optimized for transfection efficiency and AAV2 production. Purification based on filtration and chromatography was developed. Options were compared for the affinity and ion exchange-based purification steps. Finally, a new analytical SPR-based assay was developed to quantitate AAV.

Available On-Demand

Subscribe to The Medicine Maker Newsletters

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine